GILD
Gilead SciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case: Durable HIV revenue growth, stronger-than-expected adoption of long‑acting therapies (e.g., Cabenuva), and positive late‑stage readouts drive margin expansion and multiple re-rating toward the top analyst target.
Posture
Mixed
Lead driver
Value
What changed
4 setup hits (3d) with net bullish as of 2026-06-02.
What can break
HIV pricing pressure and competitive share loss
Momentum
35
Value
64
Sentiment
61
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $146.84 · Bull $170.00 · Bear $103.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-11 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $158.08
Why
Momentum35 · Δ7d -0.7
Value64 · Δ7d +0.4
Sentiment61 · Δ7d +5.9
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
35
34% active weight
Current posture
7d trendFlat
Δ7d
-0.7
Δ21d
+14.1
Value
64
32% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.7
Sentiment
61
33% active weight
Current posture
7d trendImproving
Δ7d
+5.9
Δ21d
+10.2
Why this grade
Composite grade C. Momentum 35.0 / Value 64.4 / Sentiment 60.9
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$162.77B
Beta
0.37
Shares Out
1.24B
P/E (TTM)
18.4
P/S (TTM)
5.05
P/FCF (TTM)
28.33
Rev YoY
+3.0%
EPS YoY
+143.6%
Gross Margin
+78.7%
Op Margin
+36.1%
Net Debt
$16.72B
Current Ratio
1.45
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology